Gene Therapy Market to Reach USD 36.55 Billion by 2032, Growing at a CAGR of 19.4% – MarketsandMarkets™

Delray Beach, FL, Oct. 26, 2026 (GLOBE NEWSWIRE) — MarketsandMarkets™ projects the global gene therapy market, valued at USD 7.21 billion in 2023 and USD 8.85 billion in 2024, to reach USD 36.55 billion by 2032, growing at a CAGR of 19.4% during the forecast period (2024–2032). Market growth is fueled by increasing demand for curative treatments for genetic disorders, rare diseases, and certain cancers, expanding clinical research pipelines, advances in genome editing technologies, and rising investments in biotechnology and pharmaceutical research. The development of next-generation vector delivery platforms and innovations in precision medicine are further creating opportunities for advanced gene therapy solutions.

Get PDF Brochure – Market Data & Segmentation:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

Key Market Highlights

• Market size, 2023: USD 7.21 billion
• Market size, 2024: USD 8.85 billion
• Market forecast, 2032: USD 36.55 billion
• Growth rate: CAGR of 19.4% (2024–2032)
• Leading vector segment: Viral vectors
• Leading therapeutic segment: Neurology
• Leading region: North America
• Growth opportunity: CRISPR-based genome editing, advanced vector delivery platforms, AI-optimized bioprocessing, continuous manufacturing systems, and single-use bioreactors
• Key players: Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals (Ireland), Pfizer Inc., Johnson & Johnson, Daiichi Sankyo, BioMarin, uniQure, and Amgen

Why This Market Matters
The gene therapy market is expanding as biotechnology companies, pharmaceutical manufacturers, and research institutions increasingly develop treatments designed to modify or address the underlying causes of diseases. Rising demand for curative and precision-based therapies for genetic disorders, rare diseases, and certain cancers is supporting market growth. Advances in CRISPR-based genome editing and novel vector delivery platforms are helping researchers develop innovative treatment approaches. Additionally, expanding clinical pipelines and the anticipated launch of new gene therapy products are creating opportunities for market participants. The growing emphasis on precision medicine is further strengthening the demand for gene therapies that target specific genetic conditions.

Market Overview
The gene therapy market is undergoing significant transformation as pharmaceutical companies, biotechnology firms, and research institutions invest in advanced therapeutic platforms. Viral vectors, genome editing technologies, and innovative delivery systems are becoming important components of gene therapy development. Approximately 19 new gene therapy products are expected to launch between 2026 and 2032, contributing nearly 25% of the projected market value by 2032. However, high development costs, complex manufacturing processes, small patient populations, and stringent regulatory requirements remain major challenges. The development of advanced manufacturing technologies, including AI-optimized bioprocessing, continuous manufacturing systems, and single-use bioreactors, presents opportunities to improve production efficiency and support market expansion.

Analyst Perspective
The gene therapy industry is moving toward advanced treatment platforms that combine genome editing, innovative vector technologies, and precision medicine approaches. These technologies are helping researchers develop targeted treatments for genetic disorders, rare diseases, and certain cancers. Growing clinical research investments and the anticipated introduction of new gene therapy products are expected to support market expansion. At the same time, high treatment prices, manufacturing complexity, and regulatory requirements remain important challenges. Companies that combine innovative therapeutic platforms, efficient manufacturing capabilities, and scalable delivery technologies are positioned to benefit from the market’s expansion.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962

Segment Analysis
By vector type, the viral vectors segment accounted for the largest share of the gene therapy market in 2023 and was also the fastest-growing vector segment. High efficacy and broad clinical applications are supporting the adoption of viral vectors in gene therapy development.

By therapeutic area, neurology accounted for the largest share of the market in 2023, driven by the development of gene therapies targeting neuromuscular diseases such as spinal muscular atrophy and Duchenne muscular dystrophy. Increasing research into genetic neurological disorders and the demand for targeted treatment options are supporting segment growth.

By region, North America accounted for the largest share of the gene therapy market, supported by established regulatory infrastructure, a strong biotechnology industry presence, and accelerated product approvals. Continued investments in clinical research and advanced therapeutic development are contributing to regional market growth.

Regional Analysis
North America represents the leading regional market for gene therapy, supported by established regulatory infrastructure, a strong biotechnology industry presence, and continued development and approval of innovative therapies. The region’s research capabilities and pharmaceutical investments contribute to the advancement of gene therapy products. Increasing clinical research activity and the development of treatments for genetic disorders, rare diseases, and certain cancers are supporting market expansion. Continued investment in manufacturing capabilities and advanced therapeutic technologies is expected to create further opportunities across the region.

Key Industry Trends

• Increasing adoption of CRISPR-based genome editing technologies
• Growing development of viral vector delivery platforms
• Expanding clinical pipelines for genetic disorders, rare diseases, and cancer
• Increasing demand for curative and precision-based treatment approaches
• Growing investments in gene therapy manufacturing infrastructure
• Rising adoption of AI-optimized bioprocessing and continuous manufacturing systems
• Increasing focus on cost reduction, reimbursement models, and regulatory compliance

Competitive Landscape
The competitive landscape of the gene therapy market includes established pharmaceutical companies, biotechnology firms, and specialized gene therapy developers. Major players include Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals (Ireland), Pfizer Inc., Johnson & Johnson, Daiichi Sankyo, BioMarin, uniQure, and Amgen.

These companies are involved in developing gene therapies, advanced vector technologies, and targeted treatment solutions for genetic disorders, rare diseases, and certain cancers. Competition is shaped by clinical pipeline development, product approvals, manufacturing capabilities, proprietary technology platforms, and the ability to improve treatment accessibility and production efficiency.

Recent Industry Developments

• Manufacturing Expansion: Amgen announced a USD 1 billion manufacturing expansion in North Carolina.
• Regulatory Approval: Ferring B.V. secured US FDA approval for ADSTILADRIN, an adenovirus vector therapy for bladder cancer.
• Product Approval: PTC Therapeutics received approval for KEBILIDI, a gene therapy administered directly to the brain.
• Acquisition: Novartis acquired Kate Therapeutics for USD 1.1 billion, securing proprietary capsid engineering platforms.
• Regulatory Approvals: Pfizer received US and European approvals for BEQVEZ for hemophilia B.
• Regulatory Approval: Orchard Therapeutics received US FDA approval for LENMELDY for early-onset metachromatic leukodystrophy (MLD).
• Strategic Partnership: Ginkgo Bioworks and Biogen partnered to improve the efficiency of adeno-associated virus (AAV) production platforms.

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:
Cell Therapy Technologies Market
CRISPR Market
CAR T-cell Therapy Market
Gene Transfer Technologies Market
Regenerative Medicine Market

Get access to the latest updates on Top Companies in Gene Therapy and Gene Therapy Market Size

CONTACT: About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/